Last reviewed · How we verify
Dihydroartemisinin-piperaquine with primaquine
At a glance
| Generic name | Dihydroartemisinin-piperaquine with primaquine |
|---|---|
| Also known as | DHP, PQ |
| Sponsor | Indonesia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana (NA)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
- MDA and Targeted Control Against Plasmodium Carriage in the Sahel (NA)
- Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults (PHASE2)
- Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy (PHASE2)
- Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities (NA)
- Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua (PHASE2)
- DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: